The present invention concerns a method for treating or preventing a Cutibacterium acnes bacteria-associated disease in a subject, said method comprising modulating, in particular reducing, in said subject, the ratio of the amount of C. acnes bacteria of a newly identified category called α-type to the amount of C. acnes bacteria of newly identified category called β-type, the α-type category efficiently defining acne-associated strains and the β-type defining non acne-associated strains.
Cutibacterium acnesC. acnesC. acnesC. acnes bacteria of newly identified category called ꞵ-type, the α-type category efficiently defining acne-associated strains and the ꞵ-type defining non acne-associated strains.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
3.
PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION
The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage,
wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and
wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
The present invention concerns nucleic acids of interest for modulating the microbiome of a host, to vectors encoding the nucleic acids and to methods for in vivo modulating the microbiome of a subject by delivering the nucleic acid of interest.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
10.
CUTIBACTERIUM ACNES RECOMBINANT PHAGES, METHOD OF PRODUCTION AND USES THEREOF
The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
The invention relates to methods, kits, and compositions for reducing the level of or eliminating a nucleic acid vector in situ. The invention encompasses compositions and methods for selectively eradicating nucleic acid vectors in the microbiota using packaged phagemids. The microbiota can be intestinal and the packaged phagemids can be administered orally. The phagemid encodes a nuclease or other enzyme that genetically modifies the nucleic acid vector so that the nucleic acid vector can be inactivated or eliminated.
Methods and compositions are provided for transferring a genetic circuit from one prokaryotic cell (“donor cell”) to another prokaryotic cell (“recipient cell” or “target cell”). The genetic circuit contains a nucleic acid of interest under the transcriptional control of a repressor binding sequence. The nucleic acid sequence of interest may encode a protein or RNA of interest.
A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
The invention relates to methods, kits, and compositions for reducing the level of or eliminating antimicrobial resistant (AMR) bacteria in situ. The invention encompasses compositions and methods for selectively eradicating antibiotic resistance in bacteria that carry antibiotic resistance genes in the microbiota using packaged phagemids. The microbiota can be intestinal and the packaged phagemids can be administered to a healthy subject or patient, for example, orally, rectally (e.g., in an enema), vaginally, nasally or to the skin. The phagemid encodes a nuclease or other enzyme that genetically modifies the DNA encoding the antibiotic resistance gene so that the bacteria can then be eliminated with the antibiotic.
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
The present invention concerns a method to modulate the level of or to modify a target molecule in a subject or an environment, said method comprising:
administering in said subject or providing to said environment an engineered bacterial strain comprising
(i) a heterologous or engineered nucleic acid involved in the expression of a molecule of interest, wherein the expression of said molecule of interest modulates directly or indirectly the level of or modify the target molecule in said subject or environment, and
(ii) a heterologous or engineered gene or gene set involved in the import and/or metabolism of a rare carbohydrate, wherein said heterologous gene or gene set comes from another species than the engineered bacterial strain; and
further administering to said subject, or providing to said environment, said rare carbohydrate;
whereby the level of the target molecule in said subject or environment is modulated or the target molecule is modified in said subject or environment.
The present invention concerns a method to modulate the level of or to modify a target molecule in a subject or an environment, said method comprising:
administering in said subject or providing to said environment an engineered bacterial strain comprising
(i) a heterologous or engineered nucleic acid involved in the expression of a molecule of interest, wherein the expression of said molecule of interest modulates directly or indirectly the level of or modify the target molecule in said subject or environment and
(ii) an autologous gene or gene set involved in the import and/or metabolism of a milk oligosaccharide; and
further administering to said subject, or providing to said environment, said milk oligosaccharide;
whereby the level of the target molecule in said subject or environment is modulated or the target molecule is modified in said subject or environment.
The present disclosure relates generally to genetically tagged bacterial delivery vehicles comprising unique tracer nucleic acid sequences (herein referred to as “tracers”) for use in detecting and/or quantitating the presence of two or more different said bacterial delivery vehicles within a mixture of vehicles. The present disclosure relates to methods wherein the bacterial delivery vehicles are detected through, for example, performance of multiple cycles of amplification using primers that bind to sequences within the unique tracer. Such methods can be advantageously used in quality control to detect and quantitate mixtures of bacterial delivery vehicles within a pharmaceutical composition.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
23.
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
The present invention concerns a method for reducing, in a subject or in a environment, the level of a molecule produced by at least one target bacterial strain which is harmful and/or not beneficial to said subject or environment, said method comprising: administering to the subject or providing the environment with an engineered bacterial strain, wherein said engineered bacterial strain comprises a heterologous or engineered gene or gene set providing a competitive advantage over the target bacterial strain(s), wherein said engineered bacterial strain does not produce said molecule produced by the target bacterial strain(s), and wherein said engineered bacterial strain and said target bacterial strain(s) are from the same species, whereby the level of the molecule produced by the target bacterial strain(s) is reduced in the subject or environment.
BacteroidesBacteroidesBacteroidesBacteroidesBacteroidesBacteroides strain (i) does not contain any gene encoding ꞵ-galactosidase, (ii) contains gene(s) encoding a non or less immunogenic ꞵ-galactosidase or (iii) contains a non-expressed gene encoding an immunogenic ꞵ-galactosidase.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one one bacteriocin and/or endolysin preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one one bacteriocin and/or endolysin for use in the treatment of subacute cutaneous lupus erythematosus in a subject, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the treatment of subacute cutaneous lupus erythematosus in the subject.
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use in the treatment of cutaneous T-cell lymphoma (CTCL) in a subject, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the treatment of CTCL in said subject.
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
The present invention concerns a method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein said postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing said at least one bacteriocin and/or endolysin and wherein said postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one one bacteriocin and/or endolysin preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use in the treatment of acneiform rash in a subject, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the treatment of acneiform rash in the subject.
The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
The present invention concerns nucleic acids of interest for modulating the microbiome of a host, to vectors encoding said nucleic acids and to methods for in vivo modulating the microbiome of a subject by delivering said nucleic acid of interest.
The present invention concerns nucleic acids of interest for modulating the microbiome of a host, to vectors encoding said nucleic acids and to methods for in vivo modulating the microbiome of a subject by delivering said nucleic acid of interest.
The present disclosure provides a chimeric receptor binding protein (RBP) resistant to proteolytic digestion wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion.
The present disclosure provides a chimeric receptor binding protein (RBP) resistant to proteolytic digestion wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion.
The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.
The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
The present invention concerns nucleic acids of interest for modulating the microbiome of a host, to vectors encoding the nucleic acids and to methods for in vivo modulating the microbiome of a subject by delivering the nucleic acids of interest.
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A01K 67/00 - Rearing or breeding animals, not otherwise provided forNew or modified breeds of animals
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/76 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for ActinomycesVectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Streptomyces
The present disclosure provides a chimeric receptor binding protein (RBP) resistant to proteolytic digestion wherein said RBP comprises a portion of a receptor binding protein derived from a bacteriophage fused through a designed linker region consisting of 1 to 70 amino acids, to a portion of a receptor binding protein derived from a different bacteriophage, wherein said linker region is designed to be resistant to proteolytic digestion.
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP, and/or the presence of an engineered branched receptor binding multi-subunit polypeptides (“branched-RBP”).
The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
The invention relates to methods, kits, and compositions for reducing the level of or eliminating a nucleic acid vector in situ. The invention encompasses compositions and methods for selectively eradicating nucleic acid vectors in the microbiota using packaged phagemids. The microbiota can be intestinal and the packaged phagemids can be administered orally. The phagemid encodes a nuclease or other enzyme that genetically modifies the nucleic acid vector so that the nucleic acid vector can be inactivated or eliminated.
The invention relates to methods, kits, and compositions for reducing the level of or eliminating antimicrobial resistant (AMR) bacteria in situ. The invention encompasses compositions and methods for selectively eradicating antibiotic resistance in bacteria that carry antibiotic resistance genes in the microbiota using packaged phagemids. The microbiota can be intestinal and the packaged phagemids can be administered to a healthy subject or patient, for example, orally, rectally (e.g., in an enema), vaginally, nasally or to the skin. The phagemid encodes a nuclease or other enzyme that genetically modifies the DNA encoding the antibiotic resistance gene so that the bacteria can then be eliminated with the antibiotic.
The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
in situ in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
Bacteroides sp. in the subject. The invention further encompasses methods of diagnosis of a subject as having myocarditis or dilated cardiomyopathy. The invention also encompasses compositions preventing myocarditis, treating myocarditis or dilated cardiomyopathy, or limiting progression of myocarditis toward dilated cardiomyopathy in a subject in need thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
65.
Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders
The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
The present disclosure relates generally to bacterial delivery vehicles and their use in efficient transfer of a desired payload into a target bacterial cell of the microbiota of a subject. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges that can be used to efficiently transfer the desired payload in vivo to one or more target bacterial cells of the microbiota of a subject.
The present disclosure relates generally to bacterial delivery vehicles and their use in efficient transfer of a desired payload into a target bacterial cell of the microbiota of a subject. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges that can be used to efficiently transfer the desired payload in vivo to one or more target bacterial cells of the microbiota of a subject.
The present disclosure relates generally to genetically tagged bacterial delivery vehicles comprising unique tracer nucleic acid sequences (herein referred to as “tracers”) for use in detecting and/or quantitating the presence of two or more different said bacterial delivery vehicles within a mixture of vehicles. The present disclosure relates to methods wherein the bacterial delivery vehicles are detected through, for example, performance of multiple cycles of amplification using primers that bind to sequences within the unique tracer. Such methods can be advantageously used in quality control to detect and quantitate mixtures of bacterial delivery vehicles within a pharmaceutical composition.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
C40B 20/08 - Direct analysis of the library members per se by physical methods, e.g. spectroscopy
The present disclosure relates generally to genetically tagged bacterial delivery vehicles comprising unique tracer nucleic acid sequences (herein referred to as "tracers") for use in detecting and/or quantitating the presence of two or more different said bacterial delivery vehicles within a mixture of vehicles. The present disclosure relates to methods wherein the bacterial delivery vehicles are detected through, for example, performance of multiple cycles of amplification using primers that bind to sequences within the unique tracer. Such methods can be advantageously used in quality control to detect and quantitate mixtures of bacterial delivery vehicles within a pharmaceutical composition.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
70.
Optimized vector for delivery in microbial populations
The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
The present disclosure relates generally to genetically tagged bacterial delivery vehicles comprising unique tracer nucleic acid sequences (herein referred to as "tracers") for use in detecting and/or quantitating the presence of two or more different said bacterial delivery vehicles within a mixture of vehicles. The present disclosure relates to methods wherein the bacterial delivery vehicles are detected through, for example, performance of multiple cycles of amplification using primers that bind to sequences within the unique tracer. Such methods can be advantageously used in quality control to detect and quantitate mixtures of bacterial delivery vehicles within a pharmaceutical composition.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
72.
TRANSCRIPTIONAL CONTROL IN PROKARYOTIC CELLS USING DNA-BINDING REPRESSORS
The present disclosure relates generally to methods and compositions for transferring a genetic circuit from one prokaryotic cell ("donor cell") to another prokaryotic cell ("recipient cell" or "target cell" which are used interchangeably herein). More specifically, the present disclosure relates to prokaryotic donor cells comprising (i) a genetic circuit of interest and (ii) one or more expressed transcriptional repressor proteins and the use of said donor cells in the efficient transfer of the genetic circuit into a prokaryotic recipient cell. The genetic circuit includes nucleic acid sequences encoding a RNA molecule or protein of interest.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present disclosure relates generally to methods and compositions for transferring a genetic circuit from one prokaryotic cell ("donor cell") to another prokaryotic cell ("recipient cell" or "target cell" which are used interchangeably herein). More specifically, the present disclosure relates to prokaryotic donor cells comprising (i) a genetic circuit of interest and (ii) one or more expressed transcriptional repressor proteins and the use of said donor cells in the efficient transfer of the genetic circuit into a prokaryotic recipient cell. The genetic circuit includes nucleic acid sequences encoding a RNA molecule or protein of interest.
The present disclosure relates generally to methods and compositions for transferring a genetic circuit from one prokaryotic cell (“donor cell”) to another prokaryotic cell (“recipient cell” or “target cell” which are used interchangeably herein). More specifically, the present disclosure relates to prokaryotic donor cells comprising (i) a genetic circuit of interest and (ii) one or more expressed transcriptional repressor proteins and the use of said donor cells in the efficient transfer of the genetic circuit into a prokaryotic recipient cell. The genetic circuit includes nucleic acid sequences encoding a RNA molecule or protein of interest.
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP, and/or the presence of an engineered branched receptor binding multi-subunit polypeptides (“branched-RBP”).
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP, and/or the presence of an engineered branched receptor binding multi-subunit polypeptides ("branched-RBP").
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP, and/or the presence of an engineered branched receptor binding multi-subunit polypeptides ("branched-RBP").
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
The present disclosure relates generally to bacterial delivery vehicles for use in efficient transfer of a desired payload into a target bacterial cell. More specifically, the present disclosure relates to bacterial delivery vehicles with desired host ranges based on the presence of a chimeric receptor binding protein (RBP) composed of a fusion between the N-terminal region of a RBP derived from a lambda-like bacteriophage and the C-terminal region of a different RBP.
The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Non-medicated toiletry preparations and cosmetic preparations; cosmetics; non-medicated skin creams; cosmetic preparations for skin regeneration; non-medicated skin serums; non-medicated skin treatment preparation for cosmetic purposes; cosmetic preparations for slimming purposes; non-medicated balms for use on skin; hair care cosmetics; cosmetic preparations for the face and body; non-medicated cosmetics and toiletry preparations active in the microbiome space Dietetic food and beverages, adapted for medical and veterinary use; diet pills; food supplements for humans and animals; medical preparations for slimming purposes; medicated supplements for foodstuffs for animals, food supplements for humans and animals produced by organic farming or made from goods produced by organic farming; Pharmaceutical products, namely, probiotic and prebiotic for maintenance of microbiome health; medical preparations for the treatment of infection, cancer, inflammatory disease, auto-immune disease and veterinary preparations for treatment of infection, cancer, inflammatory disease, auto-immune disease; sanitary preparations for medical purposes; pharmaceutical preparations for the treatment or prevention of bacterial diseases; antibacterial substances for medical use; diagnostic agents for medical use; drug delivery agents in the form of antimicrobials to eradicate bacteria carrying a targeted DNA sequence; antibodies for medical or veterinary purposes, namely, monoclonal and polyclonal antibodies for use in disease testing and treatment; cultures of microorganisms and biological tissues for medical or veterinary use; microbicides for industrial and institutional manufacturing processes; bacterial and bacteriological preparations for medical or veterinary use; chemical, biochemical or biological preparations for medical or veterinary use, namely, for the treatment of infection, cancer, inflammatory disease, auto-immune disease; preparations of cultures of microorganisms for medical and veterinary use; pharmaceutical preparations and substances for cancer treatment; diagnostic reagents for veterinary and medical use and chemical reagents for medical or veterinary use; diagnostic biomarking reagents for medical use; preparations for detecting genetic predispositions for medical use; treatment or diagnostic preparations for medical and veterinary use active in the microbiome space Surgical apparatus and instruments for medical, dental and veterinary use; diagnostics and analysis apparatus for medical use for testing DNA, RNA, microbiome and bacteria; medical instruments for analyzing and identification of bacteria; DNA and RNA testing apparatus for medical purposes; medical apparatus used in the treatment and the diagnostic of bacterial disorders; applicators for anti-bacterial preparations, namely, introducers, spatulas, syringes and needles for medical use; implantable devices for the subcutaneous release of medicated substances; samplers for medical use, namely, bacteria and blood sampling tubes, bacteria sampling pads, bacteria sampling pipettes; genetic testing apparatus for medical purposes; surgical apparatus and instruments for dental, medical and veterinary use in connection with the diagnosis and treatment of the microbiome Medical and pharmacological research services; consultation relating to pharmaceutical research and development; consultation relating to bacteriology research; development of pharmaceutical preparations and medicines; conducting clinical trials for others; research and development in the field of pharmaceuticals and biotechnology; bacteriological research and testing; biological, clinical and medical research services in the field of the diagnosis, editing, and functionalization of human or animal microbiomes; biological, clinical and medical research services in the field of the diagnosis and treatment of infection, cancer, inflammatory disease, auto-immune disease microbiome; medical research laboratory services; scientific research in the field of genetics; preparation of scientific reports with respect to biotechnology; research and development in the field of microbial manipulation and biotherapy; research and development in the field of the microbiome Medical services; veterinary services; hygienic and beauty care for human beings or animals; advice concerning animal feeding; veterinary surgical services; services concerning the care of pets namely non-medicated pet grooming; Medical analysis for treatment purposes provided by medical laboratories relating to the treatment of animals; medical information concerning veterinary pharmaceutical products; genetic analysis for medical or veterinary purposes; medical testing for the diagnosis and treatment of persons; consulting and information with respect to medicine; conducting of medical examinations for insurance purposes; medical analysis services for the diagnosis and treatment purposes provided by medical laboratories; medical services in the field of microbial manipulation and biotherapy; medical services with respect to the removal, treatment and processing of human cells and biological compounds active in the microbiome space
85.
Optimized vector for delivery in microbial populations
The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
i.ei.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Non-medicated toiletry preparations and cosmetic products;
cosmetics; non-medicated skin creams; cosmetic
preparations for skin regeneration; non-medicated skin
serums; cosmetic preparations for skin care and treatment;
cosmetic preparations for slimming; non-medicated balms;
hair care cosmetics; cosmetic preparations for the face and
body; non-medicated cosmetics and toiletry preparations
active in the microbiome space. Dietetic food and substances for medical or veterinary use;
food supplements for humans and animals; medical
preparations for slimming; medicated foodstuffs for animals:
all these goods are produced by organic farming or made from
goods produced by organic farming; Pharmaceutical products,
medical and veterinary preparations; sanitary products for
medical purposes; pharmaceutical preparations for the
treatment or prevention of bacterial diseases; antibacterial
substances for medical use; diagnostic agents for medical
use; drug delivery agents; antibodies for medical or
veterinary purposes; cultures of microorganisms and
biological tissues for medical or veterinary use;
microbicides; bacterial and bacteriological preparations
for medical or veterinary use; chemical, biochemical or
biological preparations for medical or veterinary use;
preparations of microorganisms for medical and veterinary
use; pharmaceutical preparations and substances for cancer
treatment; biological and chemical reagents for medical or
veterinary use; diagnostic biomarking reagents for medical
use; preparations for detecting genetic predispositions for
medical use; medical and veterinary preparations active in
the microbiome space. Surgical, medical, dental and veterinary apparatus and
instruments; diagnostics and analysis apparatus for medical
use; diagnostic, testing and monitoring equipment; analysis
devices for identification of bacteria for medical purposes;
DNA and RNA testing apparatus for medical purposes;
apparatus used for the study of bacterial disorders;
applicators for anti-bacterial preparations; implantable
devices for the subcutaneous release of medicated
substances; samplers for medical use; genetic testing
apparatus for medical purposes; surgical, dental, medical
and veterinary apparatus and instruments in connection with
the study and treatment of the microbiome. Medical and pharmacological research services; consultation
relating to pharmaceutical research and development;
consultation relating to bacteriology research; development
of pharmaceutical preparations and medicines; clinical
trials; research and development in the field of
pharmaceuticals and biotechnology; bacteriological research
and testing; biological, clinical and medical research
services; medical research laboratory services; scientific
research in the field of genetics; preparation of reports
with respect to biotechnology; research and development in
the field of microbial manipulation and biotherapy;
research and development in the field of the microbiome. Medical services; veterinary services; hygienic and beauty
care for human beings or animals; advice concerning animal
feeding; veterinary surgical services; services concerning
the care of pets; laboratory analysis services relating to
the treatment of animals; information concerning veterinary
pharmaceutical products; genetic analysis for medical or
veterinary purposes; medical testing for the diagnosis and
treatment of persons; consulting and information with
respect to medicine; conducting of medical examinations;
medical analysis services; medical services in the field of
microbial manipulation and biotherapy; medical services
with respect to the removal, treatment and processing of
human cells and biological compounds active in the
microbiome space; carrying out clinical trials.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Non-medicated toiletry preparations and cosmetic products;
cosmetics; non-medicated skin creams; cosmetic
preparations for skin regeneration; non-medicated skin
serums; cosmetic preparations for skin care and treatment;
non-medicated balms; hair care cosmetics; cosmetic
preparations for the face and body; non-medicated cosmetics
and toiletry preparations active in the microbiome space. Dietetic food and substances for medical or veterinary use;
food supplements for humans and animals; medical
preparations for slimming; medicated foodstuffs for animals:
all these goods are produced by organic farming or made from
goods produced by organic farming; Pharmaceutical products,
medical and veterinary preparations; sanitary products for
medical purposes; pharmaceutical preparations for the
treatment or prevention of bacterial diseases; antibacterial
substances for medical use; diagnostic agents for medical
use; drug delivery agents; antibodies for medical or
veterinary purposes; cultures of microorganisms and
biological tissues for medical or veterinary use;
microbicides; bacterial and bacteriological preparations
for medical or veterinary use; chemical, biochemical or
biological preparations for medical or veterinary use;
preparations of microorganisms for medical and veterinary
use; pharmaceutical preparations and substances for cancer
treatment; biological and chemical reagents for medical or
veterinary use; diagnostic biomarking reagents for medical
use; preparations for detecting genetic predispositions for
medical use; medical and veterinary preparations active in
the microbiome space. Surgical, medical, dental and veterinary apparatus and
instruments; diagnostics and analysis apparatus for medical
purposes; diagnostic, testing and monitoring equipment for
medical purposes; analysis devices for identification of
bacteria for medical purposes; DNA and RNA testing
apparatus for medical purposes; apparatus used for the
study of bacterial disorders; applicators for
anti-bacterial preparations; implantable devices for the
subcutaneous release of medicated substances; samplers for
medical use; genetic testing apparatus for medical
purposes; surgical, dental, medical and veterinary
apparatus and instruments in connection with the study and
treatment of the microbiome. Medical and pharmacological research services; consultation
relating to pharmaceutical research and development;
consultation relating to bacteriology research; development
of pharmaceutical preparations and medicines; conducting
clinical trials for others [scientific research]; carrying
out clinical trials; research and development in the field
of pharmaceuticals and biotechnology; bacteriological
research and examination; biological, clinical and medical
research services; medical research laboratory services;
scientific research in the field of genetics; preparation of
reports with respect to biotechnology; research and
development in the field of microbial manipulation and
biotherapy; research and development in the field of the
microbiome. Medical services; veterinary services; hygienic and beauty
care for human beings or animals; veterinary surgical
services; services concerning the care of pets; laboratory
analysis services relating to the treatment of animals;
information concerning veterinary pharmaceutical products;
genetic analysis for medical or veterinary purposes; medical
testing for the diagnosis and treatment of persons;
consulting and information with respect to medicine;
conducting of medical examinations; medical analysis
services; medical services in the field of microbial
manipulation and biotherapy; medical services with respect
to the removal, treatment and processing of human cells and
biological compounds active in the microbiome space.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Cosmetics; Non-medicated toiletry preparations and cosmetic products, namely, non-medicated skin creams; cosmetic preparations for skin regeneration; non-medicated skin serums; cosmetic preparations for skin care and treatment; non-medicated balms; hair care cosmetics; cosmetic preparations for the face and body; non-medicated cosmetics and toiletry preparations active in the microbiome space Dietetic food and substances for medical or veterinary use; food supplements for humans and animals; medical preparations for slimming; medicated foodstuffs for animals, all the foregoing goods are produced by organic farming or made from goods produced by organic farming; Pharmaceutical products, namely, probiotic and prebiotic for maintenance of microbiome health and/or for locally supply of molecule of interest; biological products, namely, bacteriophage, engineered bacteriophage, packaged phagemid, DNA inside a proteic shell for maintenance of microbiome health and/or for locally supply of molecule of interest, antibiotic, antibacterial, antiviral and antifungal agents for elimination or reduction of microorganisms, germs, bacteria, viruses and fungi; medical and veterinary preparations, namely, medical preparations for the treatment of infection, cancer, inflammatory disease, auto-immune disease and veterinary preparations for mammals, non-mammals, non-human primates, dogs, cats, horses, cows, pigs, sheep, donkeys, rabbits, ferrets, gerbils, hamsters, chinchillas, rats, mice, guinea pigs, poultry; sanitary products, namely, sanitary masks, sanitary sterilizing preparations, sanitary towels, sanitary napkins, sanitary pads, sanitary belts, sanitary panties; pharmaceutical preparations for the treatment or prevention of bacterial diseases; antibacterial substances for medical use; diagnostic agents for medical use; drug delivery agents; antibodies for medical or veterinary purposes; cultures of microorganisms and biological tissues for medical or veterinary use; microbicides; bacterial and bacteriological preparations for medical or veterinary use; chemical, biochemical or biological preparations for medical or veterinary use; preparations of microorganisms for medical and veterinary use; pharmaceutical preparations and substances for cancer treatment; biological and chemical reagents for medical or veterinary use; diagnostic biomarking reagents for medical use; preparations for detecting genetic predispositions for medical use; medical and veterinary preparations active in the microbiome space Surgical, medical, dental and veterinary apparatus and instruments; diagnostics and analysis apparatus for testing human or animal microbiomes for medical purposes for medical purposes; diagnostic, testing and monitoring equipment for testing human or animal microbiomes for medical purposes; analysis devices for identification of bacteria for medical purposes; DNA and RNA testing apparatus for medical purposes; apparatus used for the study of bacterial disorders; applicators for anti-bacterial preparations; implantable devices for the subcutaneous release of medicated substances; samplers for medical use, namely, sample preparation device for medical diagnostic uses; genetic testing apparatus for medical purposes; surgical, dental, medical and veterinary apparatus and instruments in connection with the study and treatment of the microbiome Medical and pharmacological research services; consultation in the field of pharmaceutical research and development; consultation in the field of bacteriology research; development of pharmaceutical preparations and medicines; conducting clinical trials for others in the nature of scientific research; carrying out clinical trials; research and development in the field of pharmaceuticals and biotechnology; bacteriological research and examination; biological, clinical and medical research services; medical research laboratory services; scientific research in the field of genetics; preparation of reports with respect to biotechnology; research and development in the field of microbial manipulation and biotherapy; research and development in the field of the microbiome Medical services; veterinary services; hygienic and beauty care for human beings or animals; veterinary surgical services; services concerning the care of pets, namely, dog bathing and non-medicated pet grooming; laboratory analysis services relating to the treatment of animals; providing medical information in the field of veterinary pharmaceutical products; genetic analysis for medical or veterinary purposes; medical testing for the diagnosis and treatment of persons; consulting and information in the field of medicine; conducting of medical examinations; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical services in the field of microbial manipulation and biotherapy; medical services with respect to the removal, treatment and processing of human cells and biological compounds active in the microbiome space
91.
OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
